Advances in Precision and Personalized Medicine: March 14-15, 2019

** Deadline for applications for this workshop was January 30, 2019 **


This workshop was held at SAS Hall on the campus of NC State University, Raleigh, NC.


The purpose of the workshop was to bring together experts in industry, academia, and regulatory affairs to discuss current advances and future goals in the field of precision medicine. In alignment with SAMSI’s year-long Program on Statistical, Mathematical, and Computational Methods for Precision Medicine (PMED), the speakers ranged in topics from hospital care and workflow, pharmaceutical development, observational and real-world evidence, and regulatory developments.

The conference featured world-leading presenters from industry, regulatory, and academia. Speakers covered a range of healthcare industries including hospitals, home care, insurance, Big Pharma, CROs, biotech, and mobile health.

The workshop featured two round-table discussions:
1. Lessons and Challenges in Observational Health Data: A round-table debate on the work generated by the Observed Medical Outcomes Partnership (OMOP) and the Observational Health Data Sciences and Informatics program (OHDSI). The panel was led by Rosa Gini (Agenzia regionale di sanità della Toscana, Florence, Italy), Miguel Hernan (Harvard), David Madigan (Columbia University), and Marc Suchard (UCLA).

2. Regulatory Advancements in the FDA: A panel discussion about recent developments in the FDA’s Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER). The panel was led by Telba Irony (FDA CBER).

The workshop featured a presentation speed-session for researchers to introduce their work.

Confirmed speakers for this event were:

Schedule and Supporting Media

Printed Schedule
Poster Titles

Thursday, March 14, 2019
Auditorium Room 2203, SAS Hall, N.C. State University, Raleigh, N.C.

Description Speaker Slides
Introduction and Opening Remarks David Banks, SAMSI/Duke University
Session 1: Advances in Biopharmaceuticals Sophie Guo, Deep6 AI
Boris Hayete, GNS Healthcare
Jessilyn Dunn, Duke University
Xiling Shen, Duke University
Herb Weisberg, Causalytics, LLC
Session 1: Advances in Biopharmaceuticals (continued) Lauren Drinkard, Lumeris
Jeff Painter, JiveCast
Warren Kibbe, Duke University
Plenary Panel: Lessons and Challenges in Observational Health Data Panelists
Moderator: Demissie Alemayheu, Columbia University
Rosa Gini, Agenzia Regionale di Sanità della Toscana
Miguel Hernan, Harvard University
David Madigan, Columbia University
Marc Suchard, UCLA
Session 2: Personalization in Hospital Care Madalina Fiterau, UMass Amherst
Alistair Johnson, MIT
Jeffery Fuller, UNC Health
Benjamin Villard, Oxford and University of Nagoya
Session 3: Medical Device Analytics Brian K. Walsh, Liberty University
Christoper McCann, Current Health
Paolo Piraino, Bayer AG
Rebecca Krouse, Rho
Session 4: Advances in Pharmaceuticals Derek Lawrence, Rho Inc.
Heather Kopetskie, Rho Inc.
Dukka KC, NC A&T State University
Session 5: Early Career Researcher/Poster Presentation Speed Session Bill Tian, Duke University
Mercedeh Ghadessi, Bayer Pharmaceuticals
Hai-Yan Yu, Penn State University
Jessie Sutphin, RTI
Sara Mohammad Taheri, Northeastern University
Xinyi Li, SAMSI
Stan Young, CG Stat
Hoa Le, PAREXEL Int’l/UNC-Charlotte
Poster Session and Social

Friday, March 15, 2019
Auditorium Room 2203, SAS Hall, N.C. State University, Raleigh, N.C.

Description Speaker Slides
Session 6: Advances in Industry Russell Reeve, IQVIA
Richard Zink, TARGET PharmaSolutions
Ilya Lipkovich, Eli Lilly
Session 7: Advances in Industry Glen Wright Colopy, Current Health and Oxford University
Jason Burke, UNC Healthcare
West Paul, WakeMed
Session 8: Patient Preference Studies: Advancements in Industry Rachael DiSantostefano, Johnson & Johnson
Carol Mansfield, RTI
Plenary Panel: Regulatory Advancements in the FDA Panelists
Moderator: Lisa Lavange, University of North Carolina at Chapel Hill
Telba Irony, FDA CBER
Estelle Russek-Cohen, FDA CBER
John Scott, FDA CBER
Martin Ho, FDA CBER
Closing Remarks

Questions: email